March 29, 2018 / 4:33 PM / a month ago

BRIEF-Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million

March 29 (Reuters) - ONXEO SA:

* FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR AGO

* FY RECURRING OPERATING LOSS EUR 19.2‍​ MILLION VERSUS LOSS OF EUR 23.2 MILLION YEAR AGO

* FY NET LOSS EUR 59.1‍​ MILLION VERSUS LOSS OF EUR 22.7 MILLION YEAR AGO

* END-DEC. CASH POSITION OF EUR 14.3 MILLION, COVERING CURRENT PROGRAMME UNTIL MID-2019

* LAUNCH OF PRECLINICAL STUDIES WITH FIRST MOLECULE GENERATED BY PLATON EXPECTED BEFORE END-2018

* RESULTS OF STUDY ON COMBINATION OF BELINOSTAT AND ASIDNA TO BE PRESENTED AT 2018 AACR CONGRESS

* RESULTS OF SECOND PHASE I CLINICAL STUDY WITH ASIDNA, DRIIV, EXPECTED BEFORE YEAR-END

* SAYS MIGHT BE ABLE TO LAUNCH CLINICAL TRIAL WITH BELINOSTAT AND ASIDNA COMBINATION IN 2018 Source text: bit.ly/2GWPAfS Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below